Capital International, Inc. Vir Biotechnology, Inc. Transaction History

Capital International, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$19.08 - $26.7 $472,745 - $661,545	-24,777 Reduced 62.79%	14,681 $374,000
Q1 2022 May 16, 2022	SELL	$21.19 - $40.01 $397,142 - $749,867	-18,742 Reduced 32.2%	39,458 $1.02 Million
Q4 2021 Feb 14, 2022	BUY	$30.97 - $54.03 $37,442 - $65,322	1,209 Added 2.12%	58,200 $2.44 Million
Q3 2021 Nov 15, 2021	SELL	$34.9 - $54.54 $122,045 - $190,726	-3,497 Reduced 5.78%	56,991 $2.48 Million
Q2 2021 Aug 16, 2021	SELL	$38.75 - $51.0 $197,547 - $259,998	-5,098 Reduced 7.77%	60,488 $2.86 Million
Q1 2021 May 14, 2021	SELL	$26.34 - $83.07 $462,346 - $1.46 Million	-17,553 Reduced 21.11%	65,586 $3.36 Million
Q4 2020 Feb 16, 2021	BUY	$25.51 - $43.38 $92,703 - $157,642	3,634 Added 4.57%	83,139 $2.23 Million
Q3 2020 Nov 13, 2020	BUY	$28.28 - $53.6 $2.25 Million - $4.26 Million	79,505 New	79,505 $2.73 Million

230

90.1M

1.28M

235K

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.28B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Capital International, Inc., based on Form 13F filings with the SEC.

Stay updated on Capital International, Inc. with notifications on news.